2026-06-14T03:37:44Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/204622024-11-29T07:55:25Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Perez-de-Llano, Luis
author
García-Cosío, Borja
author
CHACOS Study Grp
2024-07-11T09:10:46Z
2024-07-11T09:10:46Z
2017-11-02
Perez-De-Llano L, Cosio BG, CHACOS Study Grp. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. Respir Res. 2017 Nov 02;18:183.
10.1186/s12931-017-0667-x
1465-9921
1465-993X
Respiratory Research
http://hdl.handle.net/20.500.13003/9560
29096609
L619046921
2-s2.0-85032744946
http://hdl.handle.net/20.500.12105/20462
414334100002
Asthma-COPD ovelap (ACO) is an umbrella term that encompasses patients with COPD and eosinophilic inflammation (e-COPD) and smoking asthmatics with non-fully reversible airflow obstruction (SA). We compared the clinical characteristics and the inflammatory profile of e-COPD and SA. Patients classified as e-COPD were older and more often male and showed significantly impaired pulmonary function (likely explained by a heavier smoking habit). On the contrary, SA had more atopic features, more reversibility of airflow obstruction and higher IgE levels. The concentrations of IL-5, IL-13, IL-8, IL-6, TNF-alpha, IL17 in serum were similar between the 2 groups. However, Th2-related biomarkers (periostin, FeNO and blood eosinophils) shower higher median values in e-COPD patients. Our findings reinforce the notion that ACO is a heterogeneous disorder and, as a consequence, it might be unacceptable to offer the same treatment for two related but different conditions.
eng
Eosinophils
Periostin
COPD
Asthma
Asthma-COPD overlap
ACO
Asthma-COPD overlap is not a homogeneous disorder: further supporting data
research article